What is the median survival according to treatment used in chronic myelogenous leukemia (CML)?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print
Answer

A German study of 139 low-risk patients with CML, according to the Sokal score, indicated that new therapeutic agents have brought improvement in survival. Median survival according to treatment used was as follows:

  • Busulfan: 6 years (50 patients)

  • Hydroxyurea: 6.5 years (55 patients)

  • Interferon alfa: approximately 9.5 years (34 patients)

Some patients with molecular remissions from interferon alfa may be cured, but this can only be established over time.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!